Partnering with Manistee
Manistee is seeking an acquirer or development partner to fund Phase 2b and beyond. We are open to a sale of the company or an out-license of MTX-101.
Available under a confidentiality agreement
- Clinical study results, including the Phase 2a pilot
- Mechanism of action and laboratory data
- Phase 2b protocol and FDA correspondence
- Patent portfolio and freedom-to-operate
- Commercial assessment and valuation
Business development contact
[email protected]Send an inquiry
We use your details only to respond to your inquiry. See our privacy policy.